Introduction & Objective: Anxiety and depression are common in type 1 diabetes (T1D), but literature regarding their association with severe hypoglycemic events (SHE) and impaired awareness of hypoglycemia (IAH) is limited.

Methods: Adult (≥18 years old) continuous glucose monitor users in the T1D Exchange Registry completed online survey measures of SHE frequency, IAH, and anxiety/depression symptoms (PHQ-4). SHE cohorts were created based on SHE frequency in the past 12 months and IAH status (defined in the Table). Descriptive results (mean, standard deviation) were reported. Bivariate correlations between anxiety/depression with SHE frequency and IAH were examined using Pearson’s correlation. R

esults: Overall, higher SHE frequency was significantly associated with higher anxiety/depression (ranxiety=0.09, rdepression=0.08, rPHQ-4Total=0.09, all p<0.001); however, correlation coefficients were small. There was no significant relationship between anxiety/depression and IAH (p range=0.10-0.71). The problematic SHE cohort had higher reported anxiety/depression means (Table).

Conclusion: Although higher SHE frequency was associated with a small increase of anxiety/depressive symptoms, IAH alone was not. Findings highlight the need to better understand the complex relationship between SHE and IAH in the experience of anxiety/depression in adults with T1D.

graphic
View largeDownload slide
Disclosure

A. Boateng-Kuffour: Employee; Vertex Pharmaceuticals Incorporated. P. Callahan: Employee; Vertex Pharmaceuticals Incorporated. K. Chandarana: Employee; Vertex Pharmaceuticals Incorporated. Stock/Shareholder; Vertex Pharmaceuticals Incorporated, Novo Nordisk, Eli Lilly and Company. T. Gupta: Employee; Vertex Pharmaceuticals Incorporated. L. Chen: None. C.S. Kelly: None. H. Nguyen: None. K.S.M. Chapman: None. E.M. Cornelius: None. W. Wolf: None. W.H. Polonsky: Research Support; Abbott Diagnostics, Dexcom, Inc. Consultant; Eli Lilly and Company, Sanofi. Advisory Panel; embecta. Consultant; Vertex Pharmaceuticals Incorporated. Advisory Panel; 9am Health.

Funding

Vertex Pharmaceuticals Incorporated

© 2024 by the American Diabetes Association
2024
Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. More information is available at http://www.diabetesjournals.org/content/license.